Search
Entrectinib
go.drugbank.com/drugs/DB11986ApprovedInvestigational[L8081] It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positive solid tumors. … [L8207] Entrectinib's approved use is meant as a last line of therapy due to its accelerated approval based on early trial data.
Synonyms: N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methylpiperazin-1-yl)-2-(oxan-4-ylamino)benzamideProducts: R O Z LytrekChikungunya vaccine (live, attenuated)
go.drugbank.com/drugs/DB18701ApprovedInvestigationalIn late 2013, the first cases were identified in the Caribbean, and it has since spread to most of the Americas.[L48786] There are no approved treatments for active chikungunya virus infection. … caused by chikungunya virus.
Miglustat
go.drugbank.com/drugs/DB00419ApprovedInvestigationalMiglustat is now the first and only approved therapy for patients with Niemann-Pick disease type C (NP-C). … Miglustat, commonly marketed under the trade name Zavesca, is a drug used to treat Gaucher disease.
Synonyms: N-(n-Butyl)deoxynojirimycin, NB-DNJClesrovimab
go.drugbank.com/drugs/DB18877Approved[A273953,A273978] Clesrovimab-cfor was approved by the US FDA in June 2025 for use in infants prior to or during their first RSV season.[L53228,L53233] … [L53233] As there are no RSV vaccines approved for infant patients, nor are vaccines immediately effective in this population, clesrovimab and similar monoclonal antibodies like [nirsevimab] are designed
Lazertinib
go.drugbank.com/drugs/DB16216ApprovedInvestigational[A264289] It was approved by the FDA on August 19, 2024.[L51189] Lazertinib is used alone or in combination with other chemotherapeutic agents.[L51184] … [A264299, A264304] Lazertinib was first approved in South Korea on January 18, 2021, for the treatment of _EGFR_ T790M mutation-positive non-small cell lung cancer (NSCLC) with EGFR mutations.
Synonyms: N-(5-((4-(4-((DIMETHYLAMINO)METHYL)-3-PHENYL-1H-PYRAZOL-1-YL)PYRIMIDIN-2-YL)AMINO)-4-METHOXY-2-MORPHOLINOPHENYL)ACRYLAMIDE, 2-PROPENAMIDE, N-(5-((4-(4-((DIMETHYLAMINO)METHYL)-3-PHENYL-1H-PYRAZOL-1-YL)-2-PYRIMIDINYL)AMINO)-4-METHOXY-2-(4-MORPHOLINYL)PHENYL)-Sparsentan
go.drugbank.com/drugs/DB12548ApprovedInvestigational[L45300] On April 24, 2024, sparsentan was granted conditional marketing authorization by the European Commission for the treatment of adults with primary IgAN.[L51559] … [A257330] In February 2023, the use of sparsentan to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression was approved by the FDA under
Categories: Agents Acting on the Renin-Angiotensin SystemBisacodyl
go.drugbank.com/drugs/DB09020ApprovedInvestigational[A233290,A233300,A207700] Bisacodyl was patented on 25 September 1956[L33045] but has been used as a laxative since 1952.[A233300] … [A233300,L13362] Both bisacodyl and [picosulfate] are metabolized to the same active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM).
Products: Lax-A GoUbrogepant
go.drugbank.com/drugs/DB15328ApprovedInvestigational[A189207,A189213] Previous agents within this class were efficacious but limited by liver toxicity - this led to the development of ubrogepant, which was designed to be a hepatoxicity-free alternative … [A189195] They appear to be better tolerated, do not contribute to medication overuse headaches, and carry no apparent cardiovascular risk, making them suitable for use in patients with cardiovascular
Riltozinameran
go.drugbank.com/drugs/DB17095ApprovedInvestigational[L43922] It tends to cause less severe disease but is significantly more virulent than both the original virus and earlier variants (e.g. Delta). … It is administered in combination with [tozinameran] for active immunization against COVID-19 caused by SARS-CoV-2, including infection caused by Omicron BA.1[L45419]
Eprosartan
go.drugbank.com/drugs/DB00876ApprovedInvestigationalBy preventing the binding of angiotensin II to AT1, vascular smooth muscle relaxes and vasodilation occurs. By inhibiting norepinephrine production, blood pressure is further reduced. … Eprosartan is an angiotensin II receptor antagonist used to treat hypertension. It performs 2 actions on the renin angiotensin system.
Categories: Agents Acting on the Renin-Angiotensin SystemSynonyms: (E)-3-[2-n-butyl-1-{(4-carboxyphenyl)methyl}-1H-imidazol-5-yl]-2-(2-thienyl)methyl-2-propenoic acid